March 14, 2005
ROCHESTER, N.Y.--Bausch & Lomb (B&L) withdrew the lawsuit it filed in U.S. District Court on May 8, which originally alleged Waltham, Mass.-based Inverness Medical Innovations and its subsidiary, Freehold, N.J.-based IVC Industries, manufacture and distribute vitamin supplements that infringe upon patent rights tied to the formula behind B&Ls Ocuvite® PreserVision eye supplements. According to B&L, it received notification from Inverness declaring neither it nor IVC distribute or manufacture certain eye private label eye supplements that infringe upon the patent rights. B&L noted the dispute was quickly clarified due to a thorough internal review and prompt, direct communication by Inverness.
B&L developed the formula in conjunction with the National Eye Institute (NEI) and holds worldwide patent rights under a license agreement with the National Institutes of Health (NIH). The landmark NEI Age-Related Eye Disease Study (AREDS) showed supplementation with antioxidant vitamins (C, E and beta-carotene) plus zinc (as supplied by B&L) lowered risk of age-related macular degeneration (AMD) and its associated vision loss, but had no effect on development or progression of cataract (Arch Ophthamol. 119:1417-36, 2001).
Inverness (www.invernessmedical.com) and IVC offer OptiZinc and Eye Vitamin plus Lutein in their private label manufacturing line.
You May Also Like
Advancing gender equity in the nutraceutical industrySep 25, 2023
CRN petition to FTC: RCTs aren’t required to substantiate ‘health-benefit’ claimsSep 22, 2023
Collagen peptide ingredient solutions for seniors’ changing needs – infographicSep 19, 2023
Radicle Insights—Covid Eris and dietary supplements: separating fact from fictionSep 21, 2023